HPGC(SH:600664) Shang Hai Zheng Quan Bao·2026-02-05 17:52Core Viewpoint - The company has received approval for the listing application of the chemical raw material drug, Ferric Protein Succinylate, which marks a significant advancement in its raw material drug sector and supports its integrated development strategy in raw material and formulation [1][3]. Group 1: Drug Approval Details - The chemical raw material drug approved is Ferric Protein Succinylate, with a packaging specification of 10kg/bag and registration number Y20230001210 [1]. - The approval was granted by the National Medical Products Administration, confirming that the drug meets the relevant requirements for drug registration [1]. Group 2: R&D Investment - The company has invested approximately RMB 8.34 million (about 834.23 thousand) in the research and development of the Ferric Protein Succinylate project as of the announcement date [2]. Group 3: Market Position - As of the announcement date, there are 11 companies in China with an "A" registration status for Ferric Protein Succinylate, including the company and Jichuan Pharmaceutical Group [2]. Group 4: Strategic Impact - The approval of Ferric Protein Succinylate is expected to enhance the company's control over its raw material production and enrich its product structure, aligning with its strategic goals [3].